A Phase 1 interventional study of Romiplostim N01 and Standard Supportive Care in Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) and Delayed Platelet Engraftment, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by First Affiliated Hospital of Zhejiang University · Phase 1, Interventional, and Treatment
This is a prospective, randomized, controlled clinical study designed to evaluate the efficacy and safety of Romiplostim N01 in promoting platelet engraftment after haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) in patients with hematologic malignancies.
A total of 130 patients who undergo haplo-HSCT for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or other hematologic malignancies will be enrolled and randomized 1:1 into a treatment group and a control group. The treatment group will receive Romiplostim N01 subcutaneously once weekly at a starting dose of 5 µg/kg, with dose adjustments based on platelet counts (maximum 10 µg/kg), for up to 4 weeks or until platelet counts reach ≥100 × 10⁹/L. The control group will not receive rh-TPO or any thrombopoietin receptor agonist (TPO-RA) therapy. Supportive care including transfusions and growth factors (G-CSF, ESA) is allowed in both groups.
The primary endpoint is the cumulative platelet engraftment rate by day +21 post-transplant, defined as sustained platelet counts > 20 × 10⁹/L for at least 7 consecutive days without transfusion. Secondary endpoints include median time to platelet engraftment, median time to achieve platelet counts ≥ 50 × 10⁹/L and ≥ 100 × 10⁹/L, total platelet transfusion volume, erythroid and neutrophil responses within 4 weeks, and overall hematopoietic recovery. Safety endpoints include the incidence of adverse events, thromboembolic events, and treatment-related serious adverse events.
The study aims to determine whether early administration of Romiplostim N01 can accelerate platelet recovery and reduce bleeding risk in patients undergoing haplo-HSCT, thereby improving post-transplant outcomes.
2,971 studies on the registry are indexed under Leukemia, Myeloid, Acute; 745 are open to participants now.
This study's planned enrollment of 130 is above the median of 41 across 2,509 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →First Affiliated Hospital of Zhejiang University is the lead sponsor of 255 studies on the registry; 139 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with malignant hematologic diseases scheduled to undergo haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) Age ≥18 years, male or female. ECOG performance status 0-1. Estimated life expectancy >6 months. Adequate renal function, defined as:serum creatinine ≤1.5 × upper limit of normal (ULN);Blood urea nitrogen (BUN) ≤1.5 × ULN.
Adequate hepatic function, defined as:Alanine aminotransferase (ALT) ≤2 × ULN.Aspartate aminotransferase (AST) ≤2 × ULN.Total bilirubin ≤1.5 × ULN.
Ability to understand and sign informed consent, and willingness to comply with all study requirements.
Exclusion Criteria:
Uncontrolled active infection or other active malignancy that could interfere with study participation.
Severe cardiovascular disease, including:New York Heart Association (NYHA) Class III-IV heart failure;Uncontrolled hypertension or hypotension;History of or high risk for thromboembolic events.
Receiving anticoagulation therapy for thrombotic events. Known hypersensitivity to romiplostim or similar agents. Use of rh-TPO or any thrombopoietin receptor agonist (TPO-RA) within 30 days prior to enrollment.
Participation in another interventional clinical study within 30 days prior to enrollment.
Any other condition that, in the investigator's judgment, makes the patient unsuitable for the study.
Drug: Romiplostim N01 · Other: Standard Supportive Care
Other: Standard Supportive Care
Romiplostim N01 is a thrombopoietin receptor agonist (TPO-RA) administered subcutaneously once weekly to promote platelet recovery after haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT). The starting dose is 5 µg/kg, adjusted up to 10 µg/kg according to platelet response. Treatment continues for up to 4 weeks or until platelet counts reach ≥100 × 10⁹/L without transfusion. Standard post-transplant supportive care is provided to all participants.
Participants in the control arm will receive standard post-transplant supportive care, including transfusions, growth factors (G-CSF, ESA), and infection prophylaxis as clinically indicated, but will not receive Romiplostim or any other thrombopoietin receptor agonist.
Cumulative Platelet Engraftment Rate by Day +21 after Haploidentical HSCT
Platelet engraftment is defined as achieving a sustained platelet count \>20 × 10⁹/L for at least 7 consecutive days without platelet transfusion. The cumulative engraftment rate by day +21 post-transplant will be compared between the Romiplostim N01 treatment arm and the standard care control arm.
Time frame: Within 21 days after transplantation
Time to Platelet Engraftment
The number of days from transplantation to the first of 7 consecutive days with a platelet count \>20 × 10⁹/L without transfusion support.
Time frame: Up to 60 days after transplantation
Proportion of Patients Achieving Platelet Counts ≥50 × 10⁹/L and ≥100 × 10⁹/L
Time frame: Up to 60 days after transplantation
Median Time to Achieve Platelet Count ≥100 × 10⁹/L during the 4-Week Treatment Period
Time frame: Within 4 weeks after initiation of Romiplostim N01 treatment
Total Platelet Transfusion Volume
Time frame: Up to 60 days after transplantation
Proportion of Participants with Erythroid Response during the 4-Week Treatment Period
Time frame: Within 4 weeks after initiation of Romiplostim N01 treatment
Proportion of Participants with Neutrophil Response during the 4-Week Treatment Period
Time frame: Within 4 weeks after initiation of Romiplostim N01 treatment
Incidence of Thrombotic or Thromboembolic Events
Time frame: Within 4 weeks after initiation of Romiplostim N01 treatment
Incidence of Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)
Time frame: From initiation of treatment up to 100 days after transplantation
Incidence of Adverse Events (AEs)
Time frame: From initiation of Romiplostim N01 to 100 days after transplantation
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Zhejiang University